APLS

Apellis Pharmaceuticals, Inc. Common Stock

40.77

USD

APLS Earnings Reports

Positive Surprise Ratio

APLS beat 10 of 34 last estimates.

29%

Next Report

Date of Next Report

Apr 30, 2026

Estimate for Q1 26 (Revenue/ EPS)

$208.34M

-$0.35

Implied change from Q4 25 (Revenue/ EPS)

+4.21%

-25.53%

Implied change from Q1 25 (Revenue/ EPS)

+24.90%

-52.70%

Apellis Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Feb 24, 2026, APLS reported earnings of -0.47 USD per share (EPS) for Q4 25, missing the estimate of -0.38 USD, resulting in a -21.01% surprise. Revenue reached 199.91 million, compared to an expected 203.70 million, with a -1.86% difference. The market reacted with a -1.51% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 12 analysts forecast an EPS of -0.35 USD, with revenue projected to reach 208.34 million USD, implying an decrease of -25.53% EPS, and increase of 4.21% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Pharvaris N.V. Ordinary Shares

Report Date

Apr 02, 2026 For Q4 25

Estimate

-$0.63

Actual

-$0.72

Surprise

-13.69%

Innate Pharma S.A. ADS

Report Date

Apr 01, 2026 For Q1 26

Estimate

-$0.12

Actual

-$0.55

Surprise

-353.80%

MiNK Therapeutics, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.83

Actual

-$0.55

Surprise

+33.64%

Kairos Pharma, Ltd.

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.07

Surprise

-28.68%

Imunon, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$1.19

Actual

-$1.99

Surprise

-66.18%

Soligenix, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.57

Actual

-$0.28

Surprise

+50.98%

Cadrenal Therapeutics, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$1.18

Actual

-$1.43

Surprise

-20.34%

BioAtla, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$12.24

Actual

-$8.00

Surprise

+34.64%

Sunshine Biopharma Inc.

Report Date

Apr 03, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.54

Surprise

-96.08%

CNS Pharmaceuticals, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$5.19

Actual

-$10.15

Surprise

-95.50%

FAQ

What were Apellis Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Apellis Pharmaceuticals, Inc. Common Stock reported EPS of -$0.47, missing estimates by -21.01%, and revenue of $199.91M, -1.86% below expectations.

How did the market react to Apellis Pharmaceuticals, Inc. Common Stock's Q4 2025 earnings?

The stock price moved down -1.51%, changed from $22.47 before the earnings release to $22.13 the day after.

When is Apellis Pharmaceuticals, Inc. Common Stock expected to report next?

The next earning report is scheduled for Apr 30, 2026.

What are the forecasts for Apellis Pharmaceuticals, Inc. Common Stock's next earnings report?

Based on 12 analysts, Apellis Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.35 and revenue of $208.34M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.